Subtype best predictor of basal cell carcinoma invasion depth

Share this article:
Subtype Best Predictor of Basal Cell Carcinoma Invasion Depth
Subtype Best Predictor of Basal Cell Carcinoma Invasion Depth

(HealthDay News) -- Basal cell carcinoma (BCC) subtype identified on biopsy and excision specimens is the best predictor of depth of invasion, according to a study published online April 16 in the Journal of the American Academy of Dermatology.

Michael Jude Welsch, M.D., from the Penn State Milton S. Hershey Medical Center, and colleagues studied histologic specimens from 100 BCC biopsy samples. Anatomic site; histologic subtype; maximum depth of extension; contour of the lobules at the leading edge; elastosis features; and the incidence of necrosis, calcification, and ulceration were noted, and their correlation with depth of invasion was assessed.

The researchers found 62 percent concordance between the subtype of biopsy and excision specimen. The greatest mean depth was seen for micronodular tumors, followed by infiltrative, nodular, and superficial subtypes. Depth was significantly correlated to subtype from biopsy and excision, and this association was superior to age, contours of the excision specimens, presence of necrosis, and the extent of excisional solar elastosis. Depth was not correlated with gender, anatomic site, contours of biopsy specimens, elastosis color, elastosis type, the presence of ulceration, or calcification.

"Morphologic subtype has the highest correlation with depth and reporting should reflect the highest risk growth pattern if a biopsy specimen contains more than one pattern," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.